Payment overview · 2025
General Payments
$2,501.58
124 reported records · 20 companies
Healthcare provider profile · identity verified
David L Hodes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · W. NYACK, NY · NPI 1295720647
Verified facts
What the public records show
CMS Open Payments records show David L Hodes, MD received $2,501.58 in general payments during 2025 across 124 reported records.
GlaxoSmithKline, LLC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $549.65 | 22.0% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.59 | 13.3% | 16 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $255.03 | 10.2% | 15 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $193.56 | 7.7% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.95 | 6.6% | 9 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $130.76 | 5.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $117.47 | 4.7% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $103.33 | 4.1% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $98.99 | 4.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.44 | 3.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.42 | 3.3% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $79.63 | 3.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.65 | 2.3% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $54.87 | 2.2% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.99 | 1.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $41.25 | 1.6% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $36.31 | 1.4% | 2 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $27.30 | 1.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $20.58 | 0.8% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.81 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,402.59 | 123 |
| Education | $98.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $547.58 | 25 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $337.40 | 17 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $240.46 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $212.25 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $175.69 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $130.76 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.38 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $103.33 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $100.15 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $94.44 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $82.42 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $82.42 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.42 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $79.63 | 4 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.29 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $54.87 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $2.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $2.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 255 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 73 |
| Alprazolam | Alprazolam | 160 | 79 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 157 | 123 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 150 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 146 | 42 |
| Ipratropium Bromide | Ipratropium Bromide | 132 | 50 |
| Ezetimibe | Ezetimibe | 97 | 37 |
| Montelukast Sodium | Montelukast Sodium | 96 | 35 |
| Mometasone Furoate | Mometasone Furoate | 82 | 46 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 36 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 66 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 20 |
| Simvastatin | Simvastatin | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 11 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Omeprazole | Omeprazole | 46 | 17 |
| Trazodone Hcl | Trazodone Hcl | 42 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 16 |
| Losartan Potassium | Losartan Potassium | 31 | suppressed |
| Famotidine | Famotidine | 30 | 11 |
| Dulera | Mometasone/Formoterol | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | 16 |
| Celecoxib | Celecoxib | 18 | 12 |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,501.58 · 124 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CHARTIS CATHETER, COMIRNATY, Cologuard Collection Kit, DUPIXENT, ENTRESTO, FASENRA, GLASSIA, INSPIRE, JASCAYD, LEQVIO, NUCALA, OPSUMIT, OTEZLA, Ohtuvayre, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, REPATHA, SMARTVEST, TELEPATCH CARDIAC MONITOR, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, Xhance, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error